Table 1 Baseline characteristics of included studies
Authors | Year | N | Age | Sex(M/F) | Chemotherapy | PCI | Thoracic radiotherapy | Brain metastasis | Outcomes | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PCI | Control | regimen | Y/N | Y | N | Y | N | Y | N | |||||
Shu | 2016 | 46 | 60.4 | 35/11 | EP/IP | 46/0 | 6 | 40 | 20 | 26 | 11 | 35 | SR, OS, ORR | |
Huang | 2015 | 73 | NR | 60/13 | NR | 70/3 | 20 | 53 | 30 | 43 | 24 | 49 | SR, OS | |
Bai | 2015 | 188 | 59 (22–81) | 115/73 | EP | NR | 110 | 78 | 107 | 81 | NR | NR | SR, OS | |
Wu | 2015 | 302 | 61 (34–81) | 212/43 | EP/EC | 219/56 | 34 | 241 | 109 | 166 | 60 | 215 | SR, OS, ORR | |
Salama | 2016 | 85 | 60 (39–77) | 38/47 | Sunitinib | 44/41 | 41 | 44 | NR | NR | NR | NR | SR, OS, ORR | |
Nicholls | 2016 | 129 | 65.4 | NA | EC | 101/28 | 43 | 86 | 63 | 66 | 39 | 90 | OS, DFS | |
Rule | 2015 | 71 | 73 (70–80) | NA | EP | 71/0 | 27 | 44 | NA | NA | NR | NR | OS, ORR | |
Schild | 2012 | 318 | 62 | NA | EP | 318/0 | 124 | 194 | NA | NA | NR | NR | OS, ORR | |
Sharma | 2017 | 4257 | NR | 2065/2192 | standard chemotherapy | 4257/0 | 473 | 3784 | NR | NR | 0 | 4257 | OS, ORR | |
Slotman | 2007 | 286 | 62 (37–75) | 63 (39–75) | 179/107 | standard chemotherapy | 286/0 | 143 | 143 | NR | NR | 0 | 286 | SR, OS, DFS |
Toshiaki | 2017 | 224 | 69 (43–83) | 69 (37–86) | 193/31 | platinum-based chemotherapy | 224/0 | 113 | 111 | NR | NR | 0 | 224 | OS, ORR |
Chen | 2016 | 204 | 57 (50–62) | 59 (53–64) | 171/33 | platinum-based chemotherapy | 204/0 | 45 | 159 | NR | NR | 17 | 187 | OS, ORR |
Wang | 2014 | 93 | 61 (33–82) | 74/19 | EP | 90/3 | 26 | 67 | 56 | 37 | 50 | 43 | SR, OS, ORR | |
Adriana | 2018 | 46 | 65 (42–81) | 27/19 | platinum-based chemotherapy | 46/0 | 16 | 30 | 2 | 44 | 0 | 46 | OS, PFS | |